Cornelis J M Melief

List of Publications by Year
in descending order

54 papers	8,532 citations	147801 31 h-index	175258 52 g-index
54 all docs	54 docs citations	54 times ranked	10835 citing authors

#	Article	IF	Citations
1	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014, 515, 577-581.	27.8	1,705
2	Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia. New England Journal of Medicine, 2009, 361, 1838-1847.	27.0	970
3	Therapeutic cancer vaccines. Nature Reviews Cancer, 2021, 21, 360-378.	28.4	630
4	Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nature Reviews Cancer, 2016, 16, 219-233.	28.4	580
5	Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nature Reviews Cancer, 2008, 8, 351-360.	28.4	508
6	Cancer Immunotherapy by Dendritic Cells. Immunity, 2008, 29, 372-383.	14.3	474
7	High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer. Cancer Research, 2007, 67, 354-361.	0.9	369
8	Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. Clinical Cancer Research, 2008, 14, 178-187.	7.0	346
9	Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity. Clinical Cancer Research, 2008, 14, 169-177.	7.0	286
10	Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6. Cancer Research, 2004, 64, 5449-5455.	0.9	277
11	Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11895-11899.	7.1	215
12	Association of cervical cancer with the presence of CD4⁺regulatory T cells specific for human papillomavirus antigens. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12087-12092.	7.1	201
13	HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. Journal of Translational Medicine, 2013, 11, 88.	4.4	165
14	Miniâ€review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of crossâ€priming and direct priming?. European Journal of Immunology, 2003, 33, 2645-2654.	2.9	164
15	Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clinical Cancer Research, 2016, 22, 2342-2350.	7.0	132
16	Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells. Cancer Research, 2016, 76, 6017-6029.	0.9	108
17	Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28. Journal of Experimental Medicine, 2000, 192, 483-494.	8.5	100
18	Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunological Reviews, 2002, 188, 177-182.	6.0	94

#	Article	IF	Citations
19	Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligandâ€“Peptide Conjugates. Cancer Immunology Research, 2014, 2, 756-764.	3.4	83
20	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Science Translational Medicine, 2020, 12, .	12.4	83
21	Vaccine-Induced Tumor Necrosis Factorâ€“Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death. Clinical Cancer Research, 2015, 21, 781-794.	7.0	81
22	Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. Toxicology Reports, 2020, 7, 768-771.	3.3	79
23	Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression. Cancer Immunology Research, 2015, 3, 1042-1051.	3.4	68
24	Inflammasome-Dependent Induction of Adaptive NK Cell Memory. Immunity, 2016, 44, 1406-1421.	14.3	67
25	The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFÎºB activation. Nature Communications, 2015, 6, 6537.	12.8	64
26	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget, 2015, 6, 32228-32243.	1.8	58
27	Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. European Journal of Immunology, 2001, 31, 146-155.	2.9	53
28	Addition of interferonâ€Î± to the p53â€SLPÂ® vaccine results in increased production of interferonâ€Î³ in vaccinated colorectal cancer patients: A phase I/II clinical trial. International Journal of Cancer, 2013, 132, 1581-1591.	5.1	50
29	Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication. , 2018, 6, 146.		50
30	The viral context instructs the redundancy of costimulatory pathways in driving CD8+ T cell expansion. ELife, 2015, 4, .	6.0	48
31	p53: A Potential Target Antigen for Immunotherapy of Cancer. Annals of the New York Academy of Sciences, 2000, 910, 223-236.	3.8	45
32	TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. Oncotarget, 2016, 7, 67087-67100.	1.8	43
33	ISA101 and nivolumab for HPV-16⁺ cancer: updated clinical efficacy and immune correlates of response. , 2022, 10, e004232.		38
34	Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy. Cancer Immunology Research, 2014, 2, 538-546.	3.4	29
35	Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNÎ³- and TNFÎ±-Mediated Antiproliferative Effects and Necroptosis. Frontiers in Immunology, 2016, 7, 496.	4.8	26
36	A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. Journal of General Virology, 2001, 82, 2131-2142.	2.9	25

#	Article	IF	Citations
37	The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. Cancer Immunology, Immunotherapy, 2012, 61, 1953-1963.	4.2	23
38	Precision T-cell therapy targets tumours. Nature, 2017, 547, 165-167.	27.8	23
39	Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. Vaccine, 2014, 32, 1654-1660.	3.8	22
40	Smart delivery of vaccines. Nature Materials, 2018, 17, 482-483.	27.5	18
41	Synthetic Vaccine for the Treatment of Lesions Caused by High Risk Human Papilloma Virus. Cancer Journal (Sudbury, Mass), 2011, 17, 300-301.	2.0	16
42	Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System. Journal of Immunology, 2018, 201, 87-97.	0.8	16
43	Treatment of Established Lesions Caused by High-risk Human Papilloma Virus Using a Synthetic Vaccine. Journal of Immunotherapy, 2012, 35, 215-216.	2.4	15
44	Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses. Molecular Immunology, 2018, 93, 115-124.	2.2	15
45	IgG-Mediated Anaphylaxis to a Synthetic Long Peptide Vaccine Containing a B Cell Epitope Can Be Avoided by Slow-Release Formulation. Journal of Immunology, 2014, 192, 5813-5820.	0.8	14
46	CD40-Mediated Amplification of Local Immunity by Epithelial Cells Is Impaired by HPV. Journal of Investigative Dermatology, 2014, 134, 2918-2927.	0.7	13
47	BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. British Journal of Haematology, 1998, 103, 1109-1115.	2.5	9
48	Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. Cancer Immunology Research, 2021, 9, 583-597.	3.4	9
49	Editorial: Novel Strategies for Anti-Tumor Vaccines. Frontiers in Immunology, 2019, 10, 3117.	4.8	7
50	Enhancement of proliferation and downregulation of TRAIL expression on CD8⁺ T cells by ILâ€21. European Journal of Immunology, 2010, 40, 2990-2992.	2.9	6
51	Special Review: The future of Immunotherapy. Immunotherapy Advances, 2021, 1, .	3.0	5
52	Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy. Journal of Translational Medicine, 2011, 9, 107.	4.4	3
53	Selective Activation of Oxygen-Deprived Tumor-Infiltrating Lymphocytes through Local Intratumoral Delivery of CD137 Monoclonal Antibodies. Cancer Discovery, 2012, 2, 586-587.	9.4	3
54	Scientific contributions toward successful cancer immunotherapy in The Netherlands. Immunology Letters, 2014, 162, 121-126.	2.5	1